Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBP-101 plus nab-paclitaxel and gemcitabine versus placebo plus nab-paclitaxel and gemcitabine in previously untreated metastatic pancreatic ductal adenocarcinoma
2021-005790-60Phase 2Active
- Sponsor
- Panbela Therapeutics
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pancreatic adenocarcinoma (PDAC) comparing SBP-101 plus nab-paclitaxel and gemcitabine with Placebo plus nab-paclitaxel and gemcitabine (2 arms). Primary endpoint: Overall survival. Started Apr 2022; status: active.
02
Drugs
ivospemin
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2021-005790-60.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005790-60.